Hesperidin for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Hesperidin for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Hesperidin, the main plant compound in oranges and sold as a supplement for circulation and metabolic health, most clearly lowers blood fats and eases vein-related leg symptoms. Blood pressure and inflammatory markers improve mainly in people who already have a metabolic disorder; blood sugar control does not respond. Stomach upset is the main complaint. Gut bacteria must release the active form, so response varies widely between people. (Full Review)

Protocol

Standard supplemental dose
500 mg once or twice daily
Purified hesperidin; lipid and inflammatory benefit clustered at 500–1,000 mg/day
Single versus split dosing
Split dosing preferred above 500 mg/day
Matches the short half-life and reduces the colonic load driving gastrointestinal upset
Best time of day
With meals
Ideally a fat-containing meal, which slows transit and improves the poor solubility
Time to effect
Lipid and inflammatory changes
8–12 weeks
Earlier measurement is uninformative; the trials behind these effects ran eight to twelve weeks
Venous symptom relief
Days to 2 weeks
Faster than the lipid response, and the fastest-responding subjective endpoint
Insulin and fasting glucose
More than 6–8 weeks
More than eight weeks needed for insulin and more than six for fasting glucose

Benefits

Contraindications
  • Documented citrus allergy or prior hypersensitivity to citrus bioflavonoids
  • Narrow-therapeutic-index OATP2B1 substrate drugs, unless dosing can be separated
  • Active bleeding, diagnosed clotting disorder, or platelets below 50 × 10⁹/L
  • Within 7 days of scheduled surgery
  • Decompensated cirrhosis (Child-Pugh Class C) or end-stage renal disease (eGFR under 15 mL/min/1.73 m²)
  • Pregnancy beyond short-term third-trimester use, or breastfeeding
    •
Key Interactions
  • OATP2B1 substrate drugs (fexofenadine, aliskiren, atenolol, celiprolol, some statins)
  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin)
  • Calcium channel blockers (verapamil, felodipine, nifedipine)
  • CYP3A4 substrates with narrow margins (ciclosporin, tacrolimus, some antiarrhythmics)
  • Antihypertensive medication
  • Blood-pressure-lowering supplements (beetroot nitrate, garlic extract, magnesium, omega-3, potassium)
  • Lipid-lowering supplements (red yeast rice, berberine, plant sterols, soluble fibre)
  • Other flavonoid interventions (quercetin, naringin, grapefruit products)
    •

Risk & Side Effects

  • High: Gastrointestinal intolerance
    •
  • Medium: Small weight gain
    •
  • Low: Reduced absorption of co-administered oral drugs; hypersensitivity and contact dermatitis
  • Speculative: Additive bleeding risk; interference with drug metabolism via enzyme inhibition

Monitoring

Marker Target Why
LDL cholesterol < 100 mg/dL; < 70 mg/dL with existing vascular disease Primary endpoint with the strongest pooled evidence
Total cholesterol 150–200 mg/dL Second lipid endpoint reduced in pooled trials
Triglycerides < 100 mg/dL Reduced in the broader cardiometabolic synthesis
High-sensitivity C-reactive protein < 1.0 mg/L Tracks the inflammatory effect, the clearest signal after lipids
Fasting glucose and insulin Glucose 70–85 mg/dL; insulin < 6 µIU/mL Establishes metabolic status, which predicts whether any benefit will appear
HbA1c < 5.4% Confirms the pooled finding of no glycemic effect at the individual level
Alanine aminotransferase and gamma-glutamyl transferase ALT < 25 U/L (men), < 20 U/L (women); GGT < 20 U/L The liver-fat endpoint from the fatty liver disease trial
Home systolic blood pressure < 120 mmHg Detects both the intended reduction and excessive lowering on combined therapy
Platelet count 150–400 × 10⁹/L Baseline for anyone on antiplatelet or anticoagulant therapy
Body weight and waist circumference Weight: change from own baseline; waist < 94 cm (men), < 80 cm (women) Tests the pooled weight-gain signal in the individual

Cadence: Baseline, first recheck at 12 weeks, then at 6 months, then annually once a response is established; home blood pressure logged weekly for the first four weeks in anyone on antihypertensive therapy.

Qualitative Assessment

  • Leg heaviness, aching, and evening ankle swelling — the fastest-responding subjective endpoint
  • Digestive comfort in the first two weeks, since gastrointestinal intolerance is the dominant adverse effect
  • Exercise recovery and next-day muscle soreness after hard sessions
  • Perceived mental clarity and concentration, which improved in the citrus trials in older adults
  • Skin bruising or gum bleeding, relevant only for those on antiplatelet or anticoagulant therapy
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.